Opko Health Inc (OPK)
NASDAQ:OPK
Top Page
Opko Health
(NASDAQ:OPK)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.00
▼(-14.53% Downside)
Action:ReiteratedDate:03/20/26
OPK scores below average primarily due to weak financial performance (declining revenue, sustained losses, and negative free cash flow). Technicals also remain bearish with price below key moving averages and negative MACD. Offsetting factors are a more constructive earnings-call outlook driven by partnerships, nondilutive funding, strong liquidity and buybacks, plus a modestly positive governance event, but these are not yet reflected in sustained profitability or cash generation.
Positive Factors
ModeX pipeline & big-partner collaborations
Multiple ModeX clinical-stage programs plus high-value collaborations with Regeneron and Merck materially de-risk development and create scalable commercialization pathways. Large partner funding and >$1B potential milestones can convert R&D progress into durable non-dilutive revenue and strategic optionality over the medium term.
Negative Factors
Persistent revenue decline & cash burn
Sustained revenue declines and recurring net losses with consecutive years of negative operating and free cash flow indicate structural cash consumption. Unless revenue stabilizes or partner milestone inflows accelerate, the company will face ongoing funding pressure, potential equity erosion, and constrained capacity to self-fund growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
ModeX pipeline & big-partner collaborations
Multiple ModeX clinical-stage programs plus high-value collaborations with Regeneron and Merck materially de-risk development and create scalable commercialization pathways. Large partner funding and >$1B potential milestones can convert R&D progress into durable non-dilutive revenue and strategic optionality over the medium term.
Read all positive factors
Opko Health (OPK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$880.52M
Dividend YieldN/A
Average Volume (3M)2.44M
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth-9.75%
EPS Growth-31.28%
CountryUS
Employees2,997
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.04
Shares Outstanding759,067,260
10 Day Avg. Volume1,850,874
30 Day Avg. Volume2,442,025
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.76
Price to Sales (P/S)1.59
P/FCF Ratio-5.05
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit3.82
Enterprise Value/Ebitda-19.86
Forecast
1Y Price Target
$2.63Price Target Upside124.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$580.97M
Opko Health Business Overview & Revenue Model
Company Description
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratori...
How the Company Makes Money
OPKO Health generates revenue primarily through (1) diagnostics and testing services and (2) pharmaceuticals and other healthcare-related product and service commercialization, including income associated with subsidiaries and partnered programs.
...
Opko Health Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The call communicated substantial strategic and operational progress — meaningful ModeX pipeline advancement, high-value partnerships (Regeneron, Merck), nondilutive government funding (BARDA), a stronger cash position, and active share repurchases. Offsetting these positives are near-term financial pressures: YoY revenue decline driven by divestitures and milestone timing, Q4 net loss vs prior-year income, higher R&D spend and anticipated elevated costs in 2026, plus seasonal/weather impacts on Q1 volumes. Overall, the company is positioned for longer-term value creation but faces short-term headwinds as it invests through a transition year.Positive Updates
Strong liquidity and active capital return
Ended Q4 2025 with $369 million in cash and cash equivalents; deployed >$109 million in convertible note and common stock repurchases during 2025 and almost $230 million since 2024; repurchased 9.8 million shares in Q4 and 34.6 million shares for ~ $47 million in 2025; ~$113 million remaining under buyback authorization.
Negative Updates
Quarterly revenue decline and return to loss
Consolidated Q4 2025 revenue was $148.5 million vs $183.6 million in Q4 2024, a decline of ~19.1% YoY (partly due to asset sale timing). Company reported a net loss of $31.3 million ($0.04 per share) vs net income of $14 million ($0.01) in Q4 2024.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong liquidity and active capital return
Ended Q4 2025 with $369 million in cash and cash equivalents; deployed >$109 million in convertible note and common stock repurchases during 2025 and almost $230 million since 2024; repurchased 9.8 million shares in Q4 and 34.6 million shares for ~ $47 million in 2025; ~$113 million remaining under buyback authorization.
Read all positive updates
Company Guidance
OPKO guided Q1 2026 revenue of $125–$140M (services $71–$75M, pharmaceutical product $38–$45M, IP/other $15–$20M including Pfizer gross-profit share of $5–$6M) and called out weather-related volume headwinds of ~$3–$5M; Q1 total costs & expenses are expected to be $170–$180M (R&D $30–$32M, collaboration funding offset $7–$9M, depreciation & amortization ~ $24M). For full-year 2026 the company expects total revenue of $530–$560M (services $300–$312M, pharma product $160–$170M, partnering/collaboration revenue $70–$80M including Pfizer gross-profit share $34–$37M), total costs & expenses of $725–$750M, R&D of $125–$135M (partially offset by $22–$26M of BARDA/Regeneron funding), and depreciation & amortization of ~ $100M. OPKO closed the quarter with $369M of cash (repurchased 9.8M shares in Q4 and 34.6M shares for ~$47M in 2025) and has ~$113M remaining under its buyback authorization.Opko Health Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 606.88M | 713.14M | 863.50M | 1.00B | 1.77B |
| Gross Profit | 128.05M | 311.03M | 318.13M | 288.22M | 581.52M |
| EBITDA | -48.55M | 135.28M | -65.52M | -270.81M | 83.57M |
| Net Income | -225.73M | -53.22M | -188.86M | -328.40M | -30.14M |
Balance Sheet | |||||
| Total Assets | 1.93B | 2.20B | 2.01B | 2.17B | 2.40B |
| Cash, Cash Equivalents and Short-Term Investments | 369.07M | 431.94M | 95.88M | 153.19M | 134.71M |
| Total Debt | 433.60M | 504.44M | 326.56M | 305.55M | 254.75M |
| Total Liabilities | 663.99M | 834.76M | 622.48M | 605.61M | 714.59M |
| Stockholders Equity | 1.27B | 1.37B | 1.39B | 1.56B | 1.69B |
Cash Flow | |||||
| Free Cash Flow | -190.82M | -208.50M | -44.47M | -119.77M | 6.18M |
| Operating Cash Flow | -178.54M | -183.49M | -28.20M | -95.19M | 38.34M |
| Investing Cash Flow | 230.30M | 352.21M | -18.20M | 91.04M | 35.95M |
| Financing Cash Flow | -118.06M | 184.17M | -11.30M | 22.97M | -10.35M |
Opko Health Technical Analysis
Neutral
1.17
Price Trends
1.19
Negative
1.25
Negative
1.33
Negative
Market Momentum
>-0.01
Negative
50.07
Neutral
55.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPK, the sentiment is Neutral. The current price of 1.17 is above the 20-day moving average (MA) of 1.16, below the 50-day MA of 1.19, and below the 200-day MA of 1.33, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.07 is Neutral, neither overbought nor oversold. The STOCH value of 55.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OPK.
Opko Health Risk Analysis
Opko Health disclosed 54 risk factors in its most recent earnings report. Opko Health reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Opko Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $687.68M | -46.67 | -5.27% | ― | 10.15% | -295.52% | |
56 Neutral | $822.02M | -47.01 | -6.47% | ― | 14.46% | ― | |
52 Neutral | $998.26M | -2.79 | -12.64% | ― | 10.10% | -44.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $450.66M | -13.36 | -5.40% | ― | 13.60% | 74.64% | |
48 Neutral | $880.52M | -4.27 | -17.42% | ― | -9.75% | -31.28% | |
48 Neutral | $406.76M | -1.57 | -79.81% | ― | 0.21% | -233.51% |
* Healthcare Sector Average
OPK
Opko Health
1.17
-0.27
-18.75%
MYGN
Myriad Genetics
4.59
-3.42
-42.70%
NEO
NeoGenomics
8.00
-1.50
-15.79%
CDNA
CareDx
16.83
-2.33
-12.16%
FLGT
Fulgent Genetics
15.30
-3.78
-19.81%
CSTL
Castle Biosciences
23.53
2.48
11.78%
Opko Health Corporate Events
Executive/Board Changes
Opko Health Adds Independent Director to Strengthen Governance
Positive
Mar 19, 2026
On March 18, 2026, OPKO Health appointed former chief financial officer Subbarao V. Uppaluri, Ph.D., as an independent director to fill a board vacancy created by the passing of director Richard Krasno, who had served since February 2017. Uppaluri...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.